Overview

Principal investigator

Eligibility criteria

Key Inclusion Criteria:
*  Histologically confirmed grade 1-3a FL or MZL
*  Previously treated with ≥ 1 line of systemic therapy including anti-CD20 agent. Must have a documented failure to achieve at least partial response during the most recent systemic therapy or documented progressive disease after the most recent systemic therapy
*  Need for systemic therapy for FL or MZL
*  Measurable disease by computed tomography or magnetic resonance imaging
*  Adequate bone marrow, liver and renal function

Key Exclusion Criteria:
*  Transformation to aggressive lymphoma
*  Requiring ongoing need for corticosteroid treatment
*  Clinically significant cardiovascular disease
*  Prior malignancy within the past 2 years
*  Active fungal, bacterial, and/or viral infection that requires systemic therapy
*  Prior treatment with lenalidomide or drug from same class, if without response (partial or complete) or short remission duration (\< 24 months) Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Show more

Participate in this trial

Are you interested in enrolling in this study? Learn more here.

I'm Interested In Participating

For Referring Providers

Do you have a patient you think would be a good candidate for this trial? Learn more about enrolling your patient.

Contact the study coordinator

Tara Graff
Enroll your patient